INMB

4.40

0.45% -0.02

Handel nachbörslich: 4.40

Inmune Bio Inc (INMB)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$4.42

Offen:

$4.36

24-Stunden-Volumen:

394.91K

Relative Volume:

1.69

Marktkapitalisierung:

$97.56M

Einnahmen:

$155.00K

Nettoeinkommen (Verlust:

$-30.01M

KGV:

-2.8947

EPS:

-1.52

Netto-Cashflow:

$-11.98M

1W Leistung:

-7.37%

1M Leistung:

-3.51%

6M Leistung:

-42.86%

1J Leistung:

-55.73%

1-Tages-Spanne:

$4.32

$4.60

1-Wochen-Bereich:

$4.32

$5.16

52-Wochen-Spanne:

$4.32

$14.74

Inmune Bio Inc Stock (INMB) Company Profile

Firmenname

Inmune Bio Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(858) 964-3720

Adresse

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Mitarbeiter

Twitter

@INmuneBio

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

INMB's Discussions on Twitter

Vergleichen Sie INMB mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
INMB Inmune Bio Inc	4.40	97.56M	155.00K	-30.01M	-11.98M	-1.67
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-21	Eingeleitet	Alliance Global Partners	Buy
2024-09-27	Eingeleitet	Raymond James	Outperform
2024-08-22	Eingeleitet	Scotiabank	Sector Outperform
2023-06-01	Eingeleitet	Robert W. Baird	Outperform
2022-05-24	Herabstufung	B. Riley Securities	Buy → Neutral
2021-07-07	Bestätigt	Maxim Group	Buy
2021-04-21	Eingeleitet	B. Riley Securities	Buy
2021-01-22	Bestätigt	Maxim Group	Buy
2020-09-01	Eingeleitet	BTIG Research	Buy
2020-07-15	Bestätigt	H.C. Wainwright	Buy

Alle ansehen

Inmune Bio Inc Aktie (INMB) Neueste Nachrichten

Dec 20, 2024

Charles Schwab Investment Management Inc. Trims Stock Holdings in INmune Bio, Inc. (NASDAQ:INMB) - Defense World

Dec 20, 2024

INmune Bio stock hits 52-week low at $4.44 amid market challenges - Investing.com Canada

Dec 20, 2024

INmune Bio stock hits 52-week low at $4.44 amid market challenges By Investing.com - Investing.com South Africa

Dec 20, 2024

Dec 16, 2024

Institutions along with retail investors who hold considerable shares inINmune Bio, Inc. (NASDAQ:INMB) come under pressure; lose 11% of holdings value - Simply Wall St

Dec 16, 2024

Dec 11, 2024

Learn to Evaluate (INMB) using the Charts - Stock Traders Daily

Dec 11, 2024

Dec 10, 2024

INmune Bio extends rights agreement to 2025 - Investing.com India

Dec 10, 2024

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt - The Manila Times

Dec 10, 2024

INmune Bio Strengthens Balance Sheet Ahead of Crucial Alzheimer's Trial Data, Clears $15M Debt - StockTitan

Dec 10, 2024

Dec 09, 2024

INmune Bio extends rights agreement to 2025 By Investing.com - Investing.com Nigeria

Dec 09, 2024

INmune Bio Partners with OmniScience, Deploys GenAI Platform for Landmark Alzheimer's Trial - StockTitan

Dec 04, 2024

Nov 27, 2024

Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc.. - Marketscreener.com

Nov 27, 2024

INmune Bio (NASDAQ:INMB) Trading 1.7% Higher – Should You Buy? - Defense World

Nov 27, 2024

INmune Bio (NASDAQ:INMB) Trading 1.7% HigherWhat's Next? - MarketBeat

Nov 27, 2024

Nov 20, 2024

Scotiabank Initiates Coverage of INmune Bio (INMB) with Sector Outperform Recommendation - MSN

Nov 20, 2024

Nov 19, 2024

INmune Bio stock hits 52-week low at $4.76 amid market challenges - Investing.com

Nov 19, 2024

(INMB) Trading Report - Stock Traders Daily

Nov 19, 2024

Nov 13, 2024

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease - Marketscreener.com

Nov 13, 2024

INmune Bio Hits Major Milestone: 208 Patients Enrolled in Phase 2 Alzheimer's Trial | INMB Stock News - StockTitan

Nov 13, 2024

Inmune Bio Emerges as Biotech Innovator in 2023 - TipRanks

Nov 13, 2024

Nov 05, 2024

INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Call Transcript - MSN

Nov 05, 2024

Nov 03, 2024

INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat

Nov 03, 2024

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? - Simply Wall St

Nov 03, 2024

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) - Yahoo Finance UK

Nov 03, 2024

Nov 01, 2024